Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Non-Small-Cell Lung 5Colorectal Neoplasms 3Neoplasms 2Lung Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Turcot syndrome 1Solid Tumors 1Skin Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Recurrence 1Rare Tumour 1Prostatic Neoplasms 1Post-Acute COVID-19 Syndrome 1Pancreatic Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Mouth Neoplasms 1Medulloblastoma 1Lung Diseases, Interstitial 1Liver Neoplasms 1Fibrolamellar hepatocellular carcinoma 1

Interventions

tovorafenib 1gallium maltolate 1Temozolomide 1Receptors, Interleukin-8B 1Re-Irradiation 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Diffuse Intrinsic Pontine Glioma × Nivolumab × Clear all
NCT06639607 2026-06-03

PRiME II

Washington University School of Medicine

Phase 1/2 Not yet recruiting
68 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡